Preclinical Studies for Gene Therapies in Common NDDs: From Human-Based Cellular Through Mouse Models
Time: 10:30 am
day: Conference Day Two
Details:
- Neurodegenerative diseases (NDDs) in aging, on the spectrum of Alzheimer’s and Parkinson’s diseases, have unmet clinical need with no effective and safe disease modifying therapy (DMT)
- Gene-targeted therapies will move the field foward towards precision medicine
- Epigenome editing platform delivered by AAV offers the opportunity for the development of innovative therapeutics for NDDs caused by dysregulation of targeted gene expression
